Protected: Coronavirus Myths – Fact vs. Fiction
There is no excerpt because this is a protected post.
News and Events
ThermoGenesis Announces Corning’s Commercial Launch of the X-SERIES® Cell Processing Products Developed by ThermoGenesis
Innovative Density Gradient Media-Free & Buoyancy-Activated Cell Sorting (BACS) Technologies Improve Manufacturing Efficiency and Yield of Cell & Gene-Therapy Products RANCHO CORDOVA, Calif., June 23, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that, pursuant to its existing, … Continued
ThermoGenesis to Join Russell Microcap® Index
RANCHO CORDOVA, Calif., June 16, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market … Continued
ThermoGenesis Announces Filing of Patent Applications for Device that Improves the Accuracy of Lateral Flow Immunoassays (LFIA) in the Detection of COVID-19 Antibodies
RANCHO CORDOVA, Calif., June 11, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company has filed patent applications for a point-of-care device which improves the speed and accuracy of lateral flow immunoassays (LFIA) to detect COVID-19 IgM … Continued
ThermoGenesis Announces That Results of ImmuneCyte’s Licensed Neutralizing Antibody Therapeutics for COVID-19 Were Published in bioRxiv
RANCHO CORDOVA, Calif., June 8, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, the research partner of ThermoGenesis’ joint venture, ImmuneCyte, Inc., published the … Continued
ThermoGenesis Holdings Announces Change in Location of 2020 Annual Meeting of Stockholders
Telephone Access Provided for the Meeting RANCHO CORDOVA, Calif., May 28, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced a change in location of its 2020 Annual Meeting of Stockholders to be held at 9:00 AM … Continued
ThermoGenesis Holdings Announces Financial Results for First Quarter Ended March 31, 2020 and Provides Corporate Update
Net Revenues Increased 8%; Gross Profit Up 19%, Quarter over Quarter, U.S. Sales of COVID-19 Rapid Antibody Test Kits Started in May Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 14, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools … Continued
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2020 and Provide a Corporate Strategic Update
Conference Call to be Held on May 14, 2020 RANCHO CORDOVA, Calif., May 7, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 … Continued
ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on FOX40 and Other Local News Outlets
RANCHO CORDOVA, Calif., April 24, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that it was featured on multiple new outlets, including a Fox40 news segment titled, “Rancho Cordova Company Says It’s Working on Potential Treatment for Coronavirus,” regarding … Continued